Cargando…

PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers

Signal transducer and activator of transcription 5 (STAT5) signaling plays a pathogenic role in both hematologic malignancies and solid tumors. In acute myeloid leukemia (AML), internal tandem duplications of fms-like tyrosine kinase 3 (FLT3-ITD) constitutively activate the FLT3 receptor, producing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dellomo, Anna J., Abbotts, Rachel, Eberly, Christian L., Karbowski, Mariusz, Baer, Maria R., Kingsbury, Tami J., Rassool, Feyruz V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609071/ https://www.ncbi.nlm.nih.gov/pubmed/34808460 http://dx.doi.org/10.1016/j.tranon.2021.101283

Ejemplares similares

Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
por: Abbotts, Rachel, et al.
Publicado: (2022)

FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia
por: Chougule, Rohit A., et al.
Publicado: (2016)

Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress
por: Doshi, Kshama A., et al.
Publicado: (2016)

Pharmacological inhibiting STAT5 for the treatment of FLT3‐ITD‐positive acute myeloid leukemia with triciribine phosphate monohydrate
por: Wu, Hong, et al.
Publicado: (2023)

Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia
por: Kogan, Aksinija A., et al.
Publicado: (2022)

Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL
por: Dumas, Pierre-Yves, et al.
Publicado: (2019)

Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia
por: Richine, Briana M., et al.
Publicado: (2016)

STAT5-dependent regulation of CDC25A by miR-16 controls proliferation and differentiation in FLT3-ITD acute myeloid leukemia
por: Sueur, Gabrielle, et al.
Publicado: (2020)

The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia
por: Cao, Tingyong, et al.
Publicado: (2019)

Arsenic trioxide induces autophagic degradation of the FLT3-ITD mutated protein in FLT3-ITD acute myeloid leukemia cells
por: Liu, Xiao-Jian, et al.
Publicado: (2020)

PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
por: Min, Ahrum, et al.
Publicado: (2020)

SPINDOC binds PARP1 to facilitate PARylation
por: Yang, Fen, et al.
Publicado: (2021)

Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia
por: Burchert, Andreas
Publicado: (2021)

MicroRNA networks in FLT3-ITD acute myeloid leukemia
por: Hoang, Dinh Hoa, et al.
Publicado: (2022)

Pim-1 Kinase Phosphorylates and Stabilizes 130 kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication
por: Natarajan, Karthika, et al.
Publicado: (2013)

Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia
por: Al-Jamal, Hamid Ali Nagi, et al.
Publicado: (2015)

How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia
por: Haage, Tobias R., et al.
Publicado: (2023)

Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML
por: Yamatani, Kotoko, et al.
Publicado: (2022)

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia
por: Pillinger, Genevra, et al.
Publicado: (2015)

Feature genes predicting the FLT3/ITD mutation in acute myeloid leukemia
por: LI, CHENGLONG, et al.
Publicado: (2016)

Gab2 is Essential for Transformation by FLT3-ITD in Acute Myeloid Leukemia
por: Sies, Katharina, et al.
Publicado: (2019)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
por: Iannotta, R., et al.
Publicado: (2022)

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
por: Lee, Lauren Y., et al.
Publicado: (2021)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
por: Xu, Dan, et al.
Publicado: (2022)

FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia
por: Nogami, Ayako, et al.
Publicado: (2015)

The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2017)

NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid Leukemia
por: Naseem, Shano, et al.
Publicado: (2021)

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
por: Green, Alexa S., et al.
Publicado: (2015)

Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD(+) acute myeloid leukemia
por: Li, Dan, et al.
Publicado: (2020)

Outcomes of pediatric acute myeloid leukemia patients with FLT3-ITD mutations in the pre-FLT3 inhibitor era
por: Choi, Sujin, et al.
Publicado: (2020)

Essential Role of Signal Transducer and Activator of Transcription (Stat)5a but Not Stat5b for Flt3-Dependent Signaling
por: Zhang, Shuli, et al.
Publicado: (2000)

Pharmacologic inhibition of STAT5 in acute myeloid leukemia
por: Wingelhofer, Bettina, et al.
Publicado: (2018)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

The Enigmatic Function of PARP1: From PARylation Activity to PAR Readers
por: Kamaletdinova, Tatiana, et al.
Publicado: (2019)

TET-mediated DNA hydroxymethylation is negatively influenced by the PARP-dependent PARylation
por: Tolić, Anja, et al.
Publicado: (2022)

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
por: Stockard, Bradley, et al.
Publicado: (2018)

Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD(+) acute myeloid leukemia cells
por: Liu, Yi, et al.
Publicado: (2021)

Selectively targeting FLT3-ITD mutants over FLT3- wt by a novel inhibitor for acute myeloid leukemia
por: Wang, Aoli, et al.
Publicado: (2020)

CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia
por: Bertoli, Sarah, et al.
Publicado: (2015)

An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia
por: Lopez, Sophie, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_58nb17l7gtai3oiskr3va5493l